生物制剂适应症重度哮喘患者的急性加重轨迹
基于英国全国电子病历,纳入10,078例未使用过生物制剂的重度哮喘成人,识别出三种急性加重轨迹:缓解稳定型70%、慢性频繁型20%、难治频繁型10%。超三分之二患者在标准治疗下即可改善,慢性频繁型患者血嗜酸性粒细胞计数更高且在符合生物制剂标准前数年即已显现。
要点
- 生物制剂适应症患者中70%在标准治疗下急性加重可缓解至每年<3次。
- 慢性频繁型占20%,中位每年急性加重5次,血嗜酸性粒细胞计数较高。
- 难治频繁型占10%,中位每年口服糖皮质激素疗程>10次。
核心结论
- 超过三分之二的生物制剂适应症重度哮喘患者仅用标准治疗即可改善急性加重。
- 慢性频繁型患者血嗜酸性粒细胞计数更高,且在符合生物制剂标准前数年即已显现,提示为独特疾病表型。
研究设计与样本
- 基于英国全国电子病历识别未使用过生物制剂的成人重度哮喘患者。
- 第0年定义为首次满足重度哮喘标准且≥3次全身糖皮质激素治疗的急性加重(即生物制剂适应症)。
- 采用纵向k-means识别符合适应症后的急性加重轨迹,并进行敏感性分析(替代k值和较低急性加重阈值≥2次/年)。
- 共纳入10,078例生物制剂适应症成人,中位年龄51岁,女性占71%。
主要发现
- 识别出三种轨迹:缓解稳定型70%(n=7,091),即使ICS在急性加重峰值年后减少,仍持续改善至每年<3次急性加重。
- 慢性频繁型20%(n=1,969),持续频繁急性加重(中位每年5次)。
- 难治频繁型10%(n=1,018),持续高口服糖皮质激素暴露(中位每年>10个疗程)。
- 慢性频繁型第0年血嗜酸性粒细胞计数中位0.30×10^9/L,高于缓解稳定型(0.23×10^9/L)和难治频繁型(0.21×10^9/L),p<0.001。
- 缓解稳定型患者合并支气管扩张的可能性最低,其余人口学和过敏性合并症相似。
关键数值与推荐
- 生物制剂适应症定义:满足重度哮喘标准且每年≥3次全身糖皮质激素治疗的急性加重。
- 敏感性分析采用较低急性加重阈值≥2次/年,结果一致。
临床怎么用
- 对生物制剂适应症重度哮喘患者,应先评估标准治疗下的急性加重轨迹,部分患者可自行缓解。
- 血嗜酸性粒细胞计数较高者更可能表现为慢性频繁加重表型,可辅助识别需早期生物制剂干预的人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma biologics are highly effective in reducing exacerbations. Improvement in exacerbations after biologic initiation is often attributed to treatment effect. RESEARCH QUESTION: What proportion of biologic-eligible severe asthma patients improve without biologic therapy, and what characterises those who remain frequent exacerbators? STUDY DESIGN AND METHODS: Biologic-naïve adults with severe asthma were identified in nationwide UK electronic medical records. Year 0 was defined as the first year patients met severe asthma criteria with ≥3 systemic corticosteroid-treated exacerbations (biologic-eligible). Post-eligibility exacerbation trajectories were identified using longitudinal k-means. Sensitivity analyses included alternative k and a lower exacerbation threshold (≥2/year). Covariates included the highest blood eosinophil count, inhaled corticosteroid (ICS) dose and comorbidities. RESULTS: Among 10,078 biologic-eligible adults (median age 51 years; 71% female), we identified three exacerbation trajectories: (1) Remitting-stable (70%, n=7,091), with sustained improvement to <3 exacerbations/year even though ICS reduced after peak exacerbation year; (2) Chronic-frequent (20%, n=1,969), with persistently frequent exacerbations (median 5/year); (3) Refractory-frequent (10%, n=1,018), with high ongoing oral corticosteroid exposure (median >10 courses/year). Results were consistent across sensitivity analyses. Remitting-stable patients were least likely to have bronchiectasis but were otherwise similar in demographics and allergic comorbidities. Blood eosinophil count was higher in the chronic-frequent group (Year 0 median 0.30×109/L) compared with remitting-stable (0.23×109/L) and refractory-frequent groups (0.21×109/L, p<0.001); this was evident several years before meeting biologic exacerbation criteria. INTERPRETATION: Over two-thirds of biologic-eligible patients improved with standard care alone. Chronic-frequent exacerbators had higher blood eosinophil counts, even years before meeting biologic criteria, suggesting a distinct disease phenotype.
引用
- Yang F, Marshall DC, Howell I, et al. Exacerbation trajectories in biologic-eligible severe asthma patients. Chest. 2026. PMID: 42833547. doi:10.1016/j.chest.2026.09.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。